Restructuring	3 Months Ended
Dec. 30, 2023
Restructuring Costs [Abstract]
Restructuring and Related Activities Disclosure	(8) Restructuring During the first quarter of fiscal 2024, as a result of a change in strategy for a certain business within Diagnostics, including the discontinuation of the sale of certain products and expected closure of facilities, the Company determined certain fixed assets lives should be shortened and lease assets were impaired at the affected facilities. As such, the Company recorded accelerated depreciation of $7.2 million and a lease asset impairment charge of $12.5 million. The Company has initiated discussions with the respective Works Councils. In addition, the Company recorded the minimum statutory severance benefit for the affected employee groups of $1.8 million pursuant to ASC 712, Compensation Nonretirement Postemployment Benefits. The Company expects total severance benefits related to this action will be approximately $4.0 million to $8.0 million. This action is expected to be completed by the end of calendar 2024. During the first quarter of fiscal 2022, the Company finalized its decision to close its Danbury, Connecticut facility where it manufactures its Breast Health capital equipment products. The manufacturing of the Breast Health capital equipment products and all other support services are in the process of being transferred to the Company’s Newark, Delaware facility. In addition, research and development, sales and services support and administrative functions are also transferring to the Newark, Delaware and Marlborough, Massachusetts facilities. The transition is expected to be completed by the third quarter of fiscal 2025. The employees were notified of the closure during the first quarter of fiscal 2022, and the majority of employees located in Danbury were given the option to relocate to the new locations. The Company is recording severance benefits ratably over the required service period pursuant to ASC 420, Exit or Disposal Cost Obligations (ASC 420). As a result, the Company recorded severance and benefits charges of $0.5 million and $0.7 million during the three months ended December 30, 2023 and December 31, 2022, respectively. The Company estimates that total severance charges, including retention, will be approximately $5.9 million. In addition, in the first quarter of fiscal 2024, as part of exiting the building, the Company recorded facility restoration costs of $0.5 million.

Restructuring

3 Months Ended

Dec. 30, 2023

Restructuring and Related Activities Disclosure

(8) Restructuring

During the first quarter of fiscal 2024, as a result of a change in strategy for a certain business within Diagnostics, including the discontinuation of the sale of certain products and expected closure of facilities, the Company determined certain fixed assets lives should be shortened and lease assets were impaired at the affected facilities. As such, the Company recorded accelerated depreciation of $7.2 million and a lease asset impairment charge of $12.5 million. The Company has initiated discussions with the respective Works Councils. In addition, the Company recorded the minimum statutory severance benefit for the affected employee groups of $1.8 million pursuant to ASC 712, Compensation Nonretirement Postemployment Benefits. The Company expects total severance benefits related to this action will be approximately $4.0 million to $8.0 million. This action is expected to be completed by the end of calendar 2024.

During the first quarter of fiscal 2022, the Company finalized its decision to close its Danbury, Connecticut facility where it manufactures its Breast Health capital equipment products. The manufacturing of the Breast Health capital equipment products and all other support services are in the process of being transferred to the Company’s Newark, Delaware facility. In addition, research and development, sales and services support and administrative functions are also transferring to the Newark, Delaware and Marlborough, Massachusetts facilities. The transition is expected to be completed by the third quarter of fiscal 2025. The employees were notified of the closure during the first quarter of fiscal 2022, and the majority of employees located in Danbury were given the option to relocate to the new locations. The Company is recording severance benefits ratably over the required service period pursuant to ASC 420, Exit or Disposal Cost Obligations (ASC 420). As a result, the Company recorded severance and benefits charges of $0.5 million and $0.7 million during the three months ended December 30, 2023 and December 31, 2022, respectively. The Company estimates that total severance charges, including retention, will be approximately $5.9 million. In addition, in the first quarter of fiscal 2024, as part of exiting the building, the Company recorded facility restoration costs of $0.5 million.